The blood-brain barrier serves a protective role, preventing compounds in the blood from getting into the brain. But that semi-permeable membrane also keeps out therapeutic compounds. Based on work undertaken by one of NeuroPharma's principals, the firm has developed a way to bring therapies across that barrier. The company is applying its technology to Hunter syndrome, a rare genetic disorder that leads to a deficiency in an enzyme important to brain health. NeuroNanos nanotechnology aims to deliver the key enzyme through the barrier, providing a treatment for Hunter syndrome.
